Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNK Stock Price Chart Interactive Chart >
MNK Price/Volume Stats
| Current price | $10.50 | 52-week high | $31.00 |
| Prev. close | $10.70 | 52-week low | $0.10 |
| Day low | $10.45 | Volume | 15,700 |
| Day high | $10.57 | Avg. volume | 32,029 |
| 50-day MA | $13.97 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 138.30M |
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
Latest MNK News From Around the Web
Below are the latest news stories about MALLINCKRODT PLC that investors may wish to consider to help them evaluate MNK as an investment opportunity.
Walmart to Settle Opioid Claims for $3.1 BillionLitigation over opioid manufacturing and distribution has led to settlements totaling more than $54 billion |
Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms GuidanceMallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1 |
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver MeetingMallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and health economic outcomes research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization2 will be presented at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting in Wash |
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific MeetingMallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that three scientific abstracts on clinical research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting in Orlando, Florida, from November 3-6. TERLIVAZ is the first and only FDA-approved product indicated to impro |
MNK Price Returns
| 1-mo | -27.59% |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 207.92% |
| 5-year | -50.82% |
| YTD | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -77.91% |
| 2018 | -29.96% |
| 2017 | -54.72% |
Continue Researching MNK
Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...